Go to virtual 3D site

Overview


In accordance with current government guidelines on the COVID-19 pandemic, the third CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held on 23rd and 24th March 2021 as a virtual event. Genome Engineering, including zinc-finger nucleases, TALENs and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline. This meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and the pioneering applications in therapeutic genome editing. A current perspective of the applications of these rapidly developing technologies with a focus on drug discovery applications will be the meeting’s focus. The scientific program for this CRISPR in Drug Discovery meeting will include:

Large-scale CRISPR functional genomics studies for drug target identification and validation
Application of genome engineering in developing biological models of disease from single cells through to complex in vitro tissue systems and in vivo models
Cutting edge CRISPR genome engineering technologies and their emerging applications
A perspective from technology leaders toward the future therapeutic applications of genome engineering
We aim to bring together the research community working in the field of genome engineering with interests in developing and applying the technology for pharmaceutical research. Join scientists from academia, pharma, biotech and CRO’s online to hear talks given by speakers at the cutting edge of genome engineering, network at the virtual exhibition and gain strategic insights into solutions for increasing the success of drug discovery and development.


Venue: Webinar
Organiser Contact Details:
ELRIG UK

T: 07484 113971
info@elrig.org


Bassett
Mr Andrew Bassett
.
Wellcome Sanger Institute
Speaker
Bryant
Dr Christopher Bryant
Postdoctoral Fellow
Wellcome Sanger Institute
Speaker
Cooper
Dr Sarah Cooper
Senior Staff Scientist
Wellcome Sanger Institute
Speaker
Corn
Prof Jacob Corn
Principal Investigator
ETH Zürich
Speaker
Datlinger
Dr Paul Datlinger
Post Doc
CeMM Research Center for Molecular Medicine, Vienna
Speaker
Davis
Mr Richard Davis
Assistant Professor
Leiden University Medical Center
Speaker
Dhaliwal
Kam Dhaliwal
SVP Alliance Management
bit.bio
Speaker
Elling
Ulrich Elling
Principal Investigator
Institute of Molecular Biotechnology, IMBA, Vienna
Speaker
Garnett
Mathew Garnett
Senior Group Leader
Wellcome Sanger Institute
Speaker
Goncalves
Manuel Goncalves
LUMC
Speaker
Komor
Prof Alexis Komor
Assistant Professor
UCSD
Speaker
Lancaster
Dr Madeline Lancaster
MRC Investigator
MRC Laboratory of Molecular Biology, Cambridge
Speaker
Mali
Prashant Mali
UCSD
Speaker
Maratou
Dr Klio Maratou
Scientific Leader
GlaxoSmithKline
Speaker
Maresca
Marcello Maresca
AstraZeneca
Speaker
Mussolino
Claudio Mussolino
University of Freiburg
Speaker
Sienksi
Dr Greg Sienksi
AstraZeneca
Speaker
Steinmetz
Dr Lars Steinmetz
PI & Senior Scientist
EMBL
Speaker
Ward
Michael Ward
NIH/NINDS
Speaker
Wilkens
Kai Wilkens
Synthego
Speaker

Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021